ASIDE: A PHASE IIIB, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABATACEPT ADMINISTERED SUBCUTANEOUSLY AND INTRAVENOUSLY IN SUBJECTS WITH RHEUMATOID ARTHRITIS, RECEIVING BACKGROUND METHOTREXATE, AND EXPERIENCING AN INADEQUATE RESPONSE TO METHOTREXATE
Serial Number: 85063047
Word Mark: ASIDE: A PHASE IIIB, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABATACEPT ADMINISTERED SUBCUTANEOUSLY AND INTRAVENOUSLY IN SUBJECTS WITH RHEUMATOID ARTHRITIS, RECEIVING BACKGROUND METHOTREXATE, AND EXPERIENCING AN INADEQUATE RESPONSE TO METHOTREXATE
Goods and Services: IC 042. US 100 101. G & S: Medical and scientific research, namely, conducting clinical trials relating to pharmaceutical preparations for human use
Mark Drawing Code: (4) STANDARD CHARACTER MARK
Filing Date: 06/15/2010
Current Basis: 1B
Original Filing Basis: 1B
Disclaimer: NO CLAIM IS MADE TO THE EXCLUSIVE RIGHT TO USE "A PHASE IIIB, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABATACEPT ADMINISTERED SUBCUTANEOUSLY AND INTRAVENOUSLY IN SUBJECTS WITH RHEUMATOID ARTHRITIS, RECEIVING BACKGROUND METHOTREXATE, AND EXPERIENCING AN INADEQUATE RESPONSE TO METHOTREXATE" APART FROM THE MARK AS SHOWN
Type of Mark: SERVICE MARK
Register: PRINCIPAL
Live/Dead Indicator: LIVE
SiteNo: 17128